Enovis Corporation (NYSE:ENOV – Get Free Report) Director Sharon Wienbar acquired 874 shares of Enovis stock in a transaction that occurred on Tuesday, November 10th. The shares were bought at an average price of $28.43 per share, for a total transaction of $24,847.82. Following the transaction, the director owned 44,651 shares of the company’s stock, valued at $1,269,427.93. This represents a 2.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Enovis Trading Up 0.4%
NYSE ENOV traded up $0.10 on Friday, reaching $27.74. 1,205,392 shares of the company were exchanged, compared to its average volume of 1,879,055. The company has a current ratio of 2.15, a quick ratio of 1.08 and a debt-to-equity ratio of 0.82. The business’s fifty day moving average price is $20.52 and its 200 day moving average price is $23.22. The stock has a market capitalization of $1.60 billion, a P/E ratio of -3.01 and a beta of 1.31. Enovis Corporation has a fifty-two week low of $16.70 and a fifty-two week high of $31.67.
Enovis (NYSE:ENOV – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.11. Enovis had a positive return on equity of 13.23% and a negative net margin of 22.86%. The business had revenue of $558.73 million during the quarter, compared to the consensus estimate of $557.12 million. During the same period last year, the company earned $0.75 EPS. The company’s revenue for the quarter was up 1.8% on a year-over-year basis. Analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current year.
Key Stories Impacting Enovis
- Positive Sentiment: Directors Angela S. Lalor and Sharon Wienbar bought a combined 3,531 shares in transactions on November 10 and 11, investing about $100,000. Insider buying can signal confidence, though the purchases are relatively small compared with the company’s overall market value. Lalor SEC filing Wienbar SEC filing
- Neutral Sentiment: Enovis management will present at the Jefferies Global Healthcare Conference on November 17. The announcement may give investors an opportunity to hear updates, but it included no new guidance or business developments. Conference announcement
Analyst Ratings Changes
A number of equities research analysts recently issued reports on the stock. Canaccord Genuity Group dropped their price objective on shares of Enovis from $45.00 to $42.00 and set a “buy” rating for the company in a report on Friday, November 6th. Citizens Jmp reduced their target price on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating on the stock in a research note on Wednesday, September 2nd. BTIG Research lifted their target price on shares of Enovis from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Needham & Company LLC increased their price target on shares of Enovis from $34.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Finally, UBS Group reissued a “buy” rating and issued a $44.00 price target on shares of Enovis in a research note on Monday, October 5th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $38.62.
Check Out Our Latest Stock Analysis on ENOV
Institutional Trading of Enovis
Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE purchased a new stake in Enovis in the 2nd quarter valued at about $11,502,000. First National Bank of Omaha acquired a new position in Enovis in the second quarter valued at about $1,250,000. Legal & General Group Plc acquired a new position in Enovis in the second quarter valued at about $2,753,000. Man Group plc acquired a new position in Enovis in the second quarter valued at about $8,711,000. Finally, Jupiter Topco LLC purchased a new position in Enovis during the second quarter worth about $2,346,000. 98.45% of the stock is owned by institutional investors and hedge funds.
Enovis Company Profile
Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.
Recommended Stories
- Five stocks we like better than Enovis
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
